28.27
Hims Hers Health Inc stock is traded at $28.27, with a volume of 24.81M.
It is up +10.21% in the last 24 hours and up +45.80% over the past month.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
See More
Previous Close:
$25.65
Open:
$25.61
24h Volume:
24.81M
Relative Volume:
0.66
Market Cap:
$6.53B
Revenue:
$2.35B
Net Income/Loss:
$128.37M
P/E Ratio:
54.15
EPS:
0.5221
Net Cash Flow:
$57.42M
1W Performance:
+3.14%
1M Performance:
+45.80%
6M Performance:
-31.10%
1Y Performance:
-45.00%
Hims Hers Health Inc Stock (HIMS) Company Profile
Name
Hims Hers Health Inc
Sector
Phone
415-851-0195
Address
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
HIMS
Hims Hers Health Inc
|
28.27 | 6.53B | 2.35B | 128.37M | 57.42M | 0.5221 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.46 | 52.00B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.73 | 41.60B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
HLN
Haleon Plc Adr
|
9.11 | 40.43B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
ZTS
Zoetis Inc
|
82.83 | 34.72B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
UTHR
United Therapeutics Corp
|
564.94 | 23.98B | 3.18B | 1.33B | 1.04B | 27.90 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-26 | Initiated | JP Morgan | Overweight |
| Mar-10-26 | Upgrade | BofA Securities | Underperform → Neutral |
| Mar-10-26 | Upgrade | Citigroup | Sell → Neutral |
| Mar-09-26 | Upgrade | Needham | Hold → Buy |
| Feb-24-26 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-12-26 | Initiated | Evercore ISI | In-line |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Oct-21-25 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jun-23-25 | Downgrade | Needham | Buy → Hold |
| Jun-04-25 | Reiterated | Needham | Buy |
| Apr-29-25 | Downgrade | TD Cowen | Buy → Hold |
| Feb-18-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-25 | Downgrade | Citigroup | Neutral → Sell |
| Jan-07-25 | Initiated | BTIG Research | Buy |
| Dec-17-24 | Initiated | Morgan Stanley | Overweight |
| Nov-14-24 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-22-24 | Initiated | Needham | Buy |
| Aug-09-24 | Downgrade | Imperial Capital | Outperform → In-line |
| May-22-24 | Downgrade | Citigroup | Buy → Neutral |
| Apr-16-24 | Downgrade | Jefferies | Buy → Hold |
| Apr-10-24 | Initiated | Canaccord Genuity | Buy |
| Feb-28-24 | Upgrade | Imperial Capital | In-line → Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-07-23 | Initiated | Imperial Capital | In-line |
| Jul-28-23 | Initiated | TD Cowen | Outperform |
| Apr-11-23 | Initiated | Robert W. Baird | Neutral |
| Feb-09-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-08-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-08-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-17-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-07-22 | Initiated | Truist | Hold |
| Jul-15-22 | Initiated | SVB Leerink | Underperform |
| Apr-14-22 | Initiated | Guggenheim | Buy |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Mar-10-22 | Initiated | Deutsche Bank | Hold |
| Dec-02-21 | Initiated | Jefferies | Hold |
| Nov-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-06-21 | Initiated | BofA Securities | Neutral |
| May-20-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Apr-21-21 | Initiated | Truist | Hold |
| Mar-09-21 | Initiated | Credit Suisse | Neutral |
| Mar-02-21 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-21 | Initiated | Citigroup | Neutral |
| Feb-12-21 | Initiated | Piper Sandler | Neutral |
| Feb-08-21 | Initiated | Tigress Financial | Buy |
View All
Hims Hers Health Inc Stock (HIMS) Latest News
Hims & Hers Stock (HIMS) Faces a GLP-1 Test as Q1 Earnings Loom - TechStock²
Hims & Hers Health Inc (HIMS) Stock Up 10.2% and Still Undervalued -- GF Score: 75/100 - GuruFocus
Hims & Hers Health (HIMS) Set to Report Q1 Earnings with Mixed E - GuruFocus
Hims Stock Faces 15% Earnings Swing as Weight-Loss Pivot Comes Due - TechStock²
HIMS Stock Slides After Amazon Escalates GLP-1 War With Ozempic — AI Healthcare Bets In Focus Ahead Of Earnings - Stocktwits
Can Platform Expansion Support Hims & Hers Stock Before Q1 Earnings? - Yahoo Finance
Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus - Investing.com
Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus - MarketBeat
Hims & Hers launches AI agent for lab results - TechTarget
Hims adds AI for lab insights - eMarketer
What the FDA's Latest Proposal Means for Lilly, Novo, and Hims - MarketBeat
Meet Labs AI: The First AI Care Agent from Hims & Hers - Hims & Hers Newsroom
Hims & Hers Health stock price forecast: $27.22 resistance in focus as HIMS rises 2.09% - Traders Union
Investor relations - HIMS Investor Relations
EDGAR Filing Documents for 0001773751-26-000060 - SEC.gov
Hims & Hers Health stock drops 3.45% as sharp selling follows early gap down - Traders Union
Stocks Under $50 to Buy or Avoid in May 2026: Hims & Hers, Insteel, Helix EnergyNews and Statistics - IndexBox
Hims & Hers Health, Inc. (HIMS) stock drops despite market gains: Important facts to note - MSN
Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
Hims & Hers Expands DTC Platform to Broaden Access to Personal Care - The Globe and Mail
HIMS Stock Jumps Overnight: CEO Eyes Heart Attack Prediction Firm With ‘Unreal’ Value - Stocktwits
Hims Earnings: Stability Could Trigger A Squeeze (NYSE:HIMS) - Seeking Alpha
Muted trading for Hims & Hers stock as price tests $26.60 support - Traders Union
Hims & Hers Health Options Spot-On: On May 4th, 110.86K Contracts Were Traded, With 1.24 Million Open Interest - Moomoo
HIMS Faces High Short Interest at 31.78% Amid Bearish Sentiment in Healthcare Sector - GuruFocus
Hims & Hers Health, Inc. (HIMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance
Most and least shorted mid-to mega-cap healthcare stocks in May - Seeking Alpha
Hims & Hers Health stock holds steady amid support level containing downside moves - Traders Union
Bronstein, Gewirtz & Grossman, LLC Is Investigating Hims & Hers Health, Inc. (HIMS) And Encourages Investors to Connect - ACCESS Newswire
Russell 2000 Analysis: Two Stocks Face Headwinds, One Potential Outperformer - IndexBox
Is Hims & Hers Health, Inc. (HIMS) A Good Stock To Buy Now? - Insider Monkey
2026-05-03 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Hims & Hers Health, Inc. (HIMS) And Encourages Investors to Connect | NYSE:HIMS | Press Release - Stockhouse
Hims & Hers Is Down 7% After FDA Proposes New GLP-1 Drug Rules. Here’s What Investors Should Know - TIKR.com
A Look At Hims & Hers Health (HIMS) Valuation As Competition And Legal Risks Intensify - simplywall.st
Hims & Hers Health, Inc. (Derivatives): Latest News, Social Media Updates and Insights - CryptoRank
Data Breach Lawsuits Test Hims And Hers Health Valuation And Momentum - Yahoo Finance
HIMS Stock | Hims & Hers Health Price, Quote, News & Analysis - TipRanks
Hims, Hims & Hers class actions allege data breach exposed sensitive patient information - Class Action Lawsuits
Hims & Hers, Novo Nordisk: FDA GLP-1 Compounding Ruling May Actually Favor Hims (NYSE:NVO) - Seeking Alpha
+3.19% for Hims & Hers Health stock as gap higher shifts short-term outlook - Traders Union
HIMS Stock On The Mend? New Testosterone Push Builds As GLP-1 Gold Rush Gets Crowded - Stocktwits
Hims & Hers Health, Inc. (HIMS) is a top-ranked momentum stock: Should you buy? - MSN
HIMS vs. TDOC: Which Digital Health Stock Offers Better Upside Now? - The Globe and Mail
Hims & Hers Health stock price forecast: $25.00 support in focus as HIMS falls 5.66% - Traders Union
Hims & Hers Health, Inc. (NYSE:HIMS) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Hims & Hers Expands Digital-First Access to Personalized Healthcare - The Globe and Mail
Hims & Hers Health shares dip amid rising selling pressure - Traders Union
Hims & Hers Health, Inc. (HIMS) is a Top-Ranked Momentum Stock: Should You Buy? - Yahoo Finance
Hims & Hers Health, Inc. (Derivatives) Analytics: Price Dynamics, Quarterly Returns, and Annual Price Changes in USD - CryptoRank
Hims & Hers Health, Inc. (Derivatives) Exchanges HIMS Markets | Buy & Sell & Trade - CryptoRank
Why Hims & Hers Health (HIMS) Shares Are Trading Lower Today - Yahoo Finance
Hims Hers Health Inc Stock (HIMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Hims Hers Health Inc Stock (HIMS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Okupe Oluyemi | Chief Financial Officer |
Apr 20 '26 |
Option Exercise |
8.65 |
12,553 |
108,531 |
282,599 |
| Okupe Oluyemi | Chief Financial Officer |
Apr 20 '26 |
Sale |
29.96 |
19,645 |
588,615 |
262,954 |
| Okupe Oluyemi | Chief Financial Officer |
Apr 17 '26 |
Option Exercise |
5.01 |
6,184 |
30,982 |
288,051 |
| Okupe Oluyemi | Chief Financial Officer |
Apr 16 '26 |
Sale |
25.90 |
36,922 |
956,147 |
281,867 |
| Okupe Oluyemi | Chief Financial Officer |
Apr 17 '26 |
Sale |
27.83 |
18,005 |
501,158 |
270,046 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):